RBC Capital Mkts reiterated coverage on Exelixis with a new price target

10/16/24 8:34:45 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

RBC Capital Mkts reiterated coverage of Exelixis with a rating of Outperform and set a new price target of $34.00 from $30.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$EXEL

Date	Price Target	Rating	Analyst
2/24/2025	$36.00	Overweight → Equal Weight	Wells Fargo
1/27/2025	$30.00 → $40.00	Equal-Weight → Overweight	Morgan Stanley
1/24/2025		Outperform → Perform	Oppenheimer
12/20/2024	$36.00 → $40.00	Outperform → Market Perform	BMO Capital Markets
12/17/2024	$35.00 → $39.00	Buy → Neutral	BofA Securities
10/16/2024	$30.00 → $34.00	Outperform	RBC Capital Mkts
9/19/2024	$30.00	Neutral	UBS
4/11/2024	$25.00	Overweight → Equal Weight	Barclays